Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Suganami

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Therapeutic Innovation & Regulatory Science|October 23, 2025
Risk of Venous Thromboembolism with Pemafibrate in Dyslipidemia: A Nationwide, Retrospective, Cohort Study Using a Japanese Claims DatabaseKenichiro Ikeda, Mika Tada, Shun Nakano, et al.
Journal of Atherosclerosis and Thrombosis|August 4, 2024
Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison TrialWenli Dai, Qiang Lv, Qingling Li, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 6, 2025
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan, Tomohiro Sasaki, Takayuki Katsube, et al.
Diabetes Care|March 3, 2022
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin TherapyHenry N Ginsberg, Neil J Hounslow, Yusuke Senko, et al.
Diabetes, Obesity & Metabolism|March 5, 2019
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE studyEiichi Araki, Shizuya Yamashita, Hidenori Arai, et al.
Journal of Atherosclerosis and Thrombosis|December 1, 2017
Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and EuropeMariko Harada-Shiba, John J P Kastelein, G Kees Hovingh, et al.
Diabetes Care|January 5, 2018
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 TrialEiichi Araki, Shizuya Yamashita, Hidenori Arai, et al.
American Journal of Physical Anthropology|March 22, 2005
Genetic diversity of JC virus in the Saami and the Finns: implications for their population historyHiroshi Ikegaya, Huai-Ying Zheng, Pekka J Saukko, et al.
Diabetes, Obesity & Metabolism|November 25, 2017
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozinMotoshi Ouchi, Kenzo Oba, Kohei Kaku, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 28, 2023
Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and ThailandHiroshige Mikamo, Satoshi Takahashi, Yuka Yamagishi, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Therapeutic Innovation & Regulatory Science|October 23, 2025
Risk of Venous Thromboembolism with Pemafibrate in Dyslipidemia: A Nationwide, Retrospective, Cohort Study Using a Japanese Claims DatabaseKenichiro Ikeda, Mika Tada, Shun Nakano, et al.
Journal of Atherosclerosis and Thrombosis|August 4, 2024
Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison TrialWenli Dai, Qiang Lv, Qingling Li, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 6, 2025
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan, Tomohiro Sasaki, Takayuki Katsube, et al.
Diabetes Care|March 3, 2022
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin TherapyHenry N Ginsberg, Neil J Hounslow, Yusuke Senko, et al.
Diabetes, Obesity & Metabolism|March 5, 2019
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE studyEiichi Araki, Shizuya Yamashita, Hidenori Arai, et al.
Journal of Atherosclerosis and Thrombosis|December 1, 2017
Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and EuropeMariko Harada-Shiba, John J P Kastelein, G Kees Hovingh, et al.
Diabetes Care|January 5, 2018
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 TrialEiichi Araki, Shizuya Yamashita, Hidenori Arai, et al.
American Journal of Physical Anthropology|March 22, 2005
Genetic diversity of JC virus in the Saami and the Finns: implications for their population historyHiroshi Ikegaya, Huai-Ying Zheng, Pekka J Saukko, et al.
Diabetes, Obesity & Metabolism|November 25, 2017
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozinMotoshi Ouchi, Kenzo Oba, Kohei Kaku, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 28, 2023
Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and ThailandHiroshige Mikamo, Satoshi Takahashi, Yuka Yamagishi, et al.
Pageof 7